Once-daily relugolix combination therapy results in sustained reduction in symptoms and improved quality of life in women with uterine fibroids treated over 52 weeks

被引：0
|
作者：
Lukes, A. [1 ]
Venturella, R. [2 ]
Al-Hendy, A. [3 ]
Nyirady, T. [4 ]
Decleer, W. [5 ]
Petraglia, F. [6 ]
Li, Y. [7 ]
Wagman, R. B. [8 ]
Hunsche, E. [9 ]
Stewart, E. A. [10 ]
机构：
[1] Carolina Womens Res & Wellness Ctr, Obstet & Gynecol, Durham, NC USA
[2] Magna Graecia Univ Catanzaro, Obstet & Gynecol, Catanzaro, Italy
[3] Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA
[4] Bacs Kiskun Cty Teaching Hosp, Dept Obstet & Gynaecol, Kecskemet, Hungary
[5] Jan Palfijn Gen Hosp, AZ Jan Palfijn Gent, Ghent, Belgium
[6] Univ Florence, Obstet & Gynecol, Florence, Italy
[7] Myovant Sci Inc, Med Affairs Clin, Brisbane, CA USA
[8] Myovant Sci Inc, Clin Dev, Brisbane, CA USA
[9] Myovant Sci GmbH, Global Market Access & Hlth Econ Outcomes Res, Basel, Switzerland
[10] Mayo Clin, Dept Obstet & Gynecol, Rochester, MN USA
来源：
HUMAN REPRODUCTION | 2021年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
O-136
引用
收藏
页码：59 / 60
页数：2
相关论文
共 9 条
  • [1] Bone Mineral Density Changes over 52 Weeks in Perimenopausal Women with Uterine Fibroids Treated with Relugolix Combination Therapy vs Untreated Cohort
    Al-Hendy, Ayman
    McLean, Rachel
    Zhai, Dongmei
    McClung, Michael R.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (12): : 1475 - 1475
  • [2] Evaluation of Relugolix Combination Therapy to Maintain Bone Mass in Women with Uterine Fibroids Through 52 Weeks: LIBERTY Long-Term Extension Study
    McClung, Michael R.
    Santora, Arthur
    Al-Hendy, Ayman
    McKain, Laura
    Li, Yulan
    Wagman, Rachel B.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 245 - 246
  • [3] Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary
    Stewart, Elizabeth A.
    Lukes, Andrea S.
    Venturella, Roberta
    Li, Yulan
    Hunsche, Elke
    Wagman, Rachel B.
    Al-Hendy, Ayman
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (08)
  • [4] Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long-term extension study: A descriptive subgroup analysis in women with anemia at baseline
    Venturella, Roberta
    Lukes, Andrea S.
    Wu, Rui
    McLean, Rachel
    Rakov, Viatcheslav G.
    Al-Hendy, Ayman
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2024, 165 (02) : 431 - 441
  • [5] Relugolix combination therapy reduced patient-reported distress from bleeding and pelvic symptoms and improved daily activities in patients with uterine fibroids in the LIBERTY program
    Stewart, E.
    Al-Hendy, A.
    Venturella, R.
    Poindexter, A., III
    Villarroels, C.
    Li, Y.
    Wagman, R. B.
    Hunsche, E.
    Lukes, A.
    HUMAN REPRODUCTION, 2020, 35 : 11 - 12
  • [6] SUSTAINED IMPROVEMENT IN PHYSICAL FUNCTION AND QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN TREATED WITH RELUGOLIX COMBINATION THERAPY OVER 104 WEEKS: SPIRIT LONG-TERM EXTENSION STUDY.
    As-Sanie, Sawsan
    Mehedintu, Claudia
    Mathur, Vandana
    Soulban, Graziella
    Hunsche, Elke
    Imm, So Jung
    Giudice, Linda C.
    FERTILITY AND STERILITY, 2022, 118 (04) : E1 - E1
  • [7] QUALITY-OF-LIFE IMPROVEMENT WITH RELUGOLIX COMBINATION THERAPY IN PATIENTS WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS: RESULTS FROM THE LIBERTY PHASE 3 PROGRAM.
    Al-Hendy, Ayman
    Stewart, Elizabeth A.
    Venturella, Roberta
    Poindexter, Alfred, III
    Villarroel, Claudio
    Kang, Jennifer
    Wagman, Rachel B.
    Hunsche, Elke
    Lukes, Andrea S.
    FERTILITY AND STERILITY, 2020, 114 (03) : E85 - E85
  • [8] Virologic Suppression, Treatment Adherence, and Improved Quality of Life on a Once-Daily Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Patients Over 96 Weeks
    Jayaweera, Dushyantha
    DeJesus, Edwin
    Nguyen, Kim L.
    Grimm, Kristy
    Butcher, David
    Seekins, Daniel W.
    HIV CLINICAL TRIALS, 2009, 10 (06): : 375 - 384
  • [9] Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
    Silverberg, Jonathan I.
    Deleuran, Mette
    Gold, Linda S.
    Bunick, Christopher G.
    Hijnen, Dirk Jan
    Calimlim, Brian M.
    Teixeira, Henrique D.
    Platt, Andrew M.
    Grada, Ayman
    Hu, Xiaofei
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB90 - AB90
1